Effectiveness of MF59™-adjuvanted subunit influenza vaccine in preventing hospitalisations for cardiovascular disease, cerebrovascular disease and pneumonia in the elderly
- 1 October 2007
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 25 (42), 7313-7321
- https://doi.org/10.1016/j.vaccine.2007.08.039
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- MF59-adjuvanted influenza vaccine confers superior immunogenicity in adult subjects (18–60 years of age) with chronic diseases who are at risk of post-influenza complicationsVaccine, 2007
- New Generation Vaccine AdjuvantsPublished by Wiley ,2007
- Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34 892 subjectsEuropean Heart Journal, 2007
- Influenza‐Associated Mortality in Hong KongClinical Infectious Diseases, 2004
- Influenza-Associated Hospitalizations in the United StatesJAMA, 2004
- Influenza and the Winter Increase in Mortality in the United States, 1959-1999American Journal of Epidemiology, 2004
- InfluenzaThe Lancet, 2003
- A New MF59-Adjuvanted Influenza Vaccine Enhances the Immune Response in the Elderly with Chronic Diseases: Results from an Immunogenicity Meta-AnalysisGerontology, 2003
- Ageing and infectionThe Lancet Infectious Diseases, 2002
- Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderlyVaccine, 1999